Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1916 1
1948 2
1949 1
1950 2
1951 3
1952 3
1953 7
1954 6
1956 3
1957 8
1958 8
1959 3
1960 2
1961 13
1962 19
1963 24
1964 32
1965 33
1966 26
1967 43
1968 56
1969 57
1970 45
1971 50
1972 39
1973 48
1974 52
1975 54
1976 47
1977 44
1978 66
1979 51
1980 64
1981 76
1982 74
1983 79
1984 76
1985 80
1986 97
1987 93
1988 95
1989 99
1990 98
1991 81
1992 102
1993 99
1994 121
1995 134
1996 156
1997 155
1998 183
1999 181
2000 199
2001 220
2002 221
2003 204
2004 243
2005 273
2006 295
2007 297
2008 259
2009 304
2010 343
2011 347
2012 380
2013 414
2014 472
2015 458
2016 444
2017 424
2018 417
2019 471
2020 585
2021 659
2022 577
2023 553
2024 546
2025 146

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,637 results

Results by year

Filters applied: . Clear all
Page 1
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
Reif A, Bitter I, Buyze J, Cebulla K, Frey R, Fu DJ, Ito T, Kambarov Y, Llorca PM, Oliveira-Maia AJ, Messer T, Mulhern-Haughey S, Rive B, von Holt C, Young AH, Godinov Y; ESCAPE-TRD Investigators. Reif A, et al. Among authors: ito t. N Engl J Med. 2023 Oct 5;389(14):1298-1309. doi: 10.1056/NEJMoa2304145. N Engl J Med. 2023. PMID: 37792613 Free article. Clinical Trial.
A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A.
Shima M, Amano K, Ogawa Y, Yoneyama K, Ozaki R, Kobayashi R, Sakaida E, Saito M, Okamura T, Ito T, Hattori N, Higasa S, Suzuki N, Seki Y, Nogami K. Shima M, et al. Among authors: ito t. J Thromb Haemost. 2023 Mar;21(3):534-545. doi: 10.1016/j.jtha.2022.10.004. Epub 2022 Dec 22. J Thromb Haemost. 2023. PMID: 36696195 Free article. Clinical Trial.
Switching on stress.
Kashiwagi K, Ito T. Kashiwagi K, et al. Among authors: ito t. Nat Chem Biol. 2024 Apr;20(4):394-395. doi: 10.1038/s41589-023-01436-w. Nat Chem Biol. 2024. PMID: 37945895 No abstract available.
[ICI-induced liver injury].
Ito T, Kawashima H. Ito T, et al. Nihon Shokakibyo Gakkai Zasshi. 2024;121(12):948-956. doi: 10.11405/nisshoshi.121.948. Nihon Shokakibyo Gakkai Zasshi. 2024. PMID: 39662922 Japanese. No abstract available.
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.
Kudo M, Ueshima K, Saeki I, Ishikawa T, Inaba Y, Morimoto N, Aikata H, Tanabe N, Wada Y, Kondo Y, Tsuda M, Nakao K, Ito T, Hosaka T, Kawamura Y, Kuzuya T, Nojiri S, Ogawa C, Koga H, Hino K, Ikeda M, Moriguchi M, Hisai T, Yoshimura K, Furuse J, Arai Y. Kudo M, et al. Among authors: ito t. Liver Cancer. 2023 Jun 5;13(1):99-112. doi: 10.1159/000531377. eCollection 2024 Feb. Liver Cancer. 2023. PMID: 38344448 Free PMC article.
Physiological and immunological barriers in the lung.
Kageyama T, Ito T, Tanaka S, Nakajima H. Kageyama T, et al. Among authors: ito t. Semin Immunopathol. 2024 Jan;45(4-6):533-547. doi: 10.1007/s00281-024-01003-y. Epub 2024 Mar 7. Semin Immunopathol. 2024. PMID: 38451292 Free PMC article. Review.
11,637 results
You have reached the last available page of results. Please see the User Guide for more information.